Canada markets closed

CSPC Pharmaceutical Group Limited (CVG.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.7022-0.0026 (-0.37%)
At close: 08:02AM CET
Full screen
Previous Close0.7048
Open0.7022
Bid0.6990 x 1500000
Ask0.7434 x 1500000
Day's Range0.7022 - 0.7022
52 Week Range0.6226 - 1.0200
Volume7,090
Avg. Volume1,840
Market Cap8.585B
Beta (5Y Monthly)0.71
PE Ratio (TTM)10.03
EPS (TTM)0.0700
Earnings DateN/A
Forward Dividend & Yield0.03 (4.80%)
Ex-Dividend DateSept 07, 2023
1y Target EstN/A
  • Reuters

    UPDATE 1-China's CSPC Pharma partners with Pfizer for oral COVID treatment

    Chinese drug maker CSPC Pharmaceutical Group said on Thursday it signed a strategic partnership with Pfizer to launch a local brand of an oral COVID-19 treatment, in an attempt to improve the access for treatment in China. The combination of Nirmatrelvir and Ritonavir sold under the brand name Paxlovid, an oral small molecule developed by pharmaceutical company Pfizer, is used to treat patients suffering from mild to moderate COVID-19 symptoms and who are at the risk of disease progression. China, whose home-grown vaccines are seen as less effective than the Moderna and Pfizer-BioNTech mRNA shots, has been racing to develop vaccines using messenger RNA (mRNA) technology since early 2020.

  • Reuters

    UPDATE 5-China OKs its first mRNA vaccine, from drugmaker CSPC

    China has approved its first domestically developed mRNA vaccine against COVID-19, CSPC Pharmaceutical Group Ltd said on Wednesday, a major achievement in a country that has declined to use Western COVID shots to support domestic research. China, whose home-grown vaccines are seen as less effective than the Moderna and Pfizer-BioNTech mRNA shots, has been racing to develop vaccines using messenger RNA (mRNA) technology since early 2020. The long-awaited approval comes as infections have fallen sharply across China since it suddenly dropped its strict "zero-COVID" curbs in December, making the sales outlook for the newly approved vaccine moderate.

  • Reuters

    China approves its first mRNA vaccine, from domestic drugmaker CSPC

    China's CSPC Pharmaceutical Group Limited said on Wednesday its messenger RNA (mRNA) COVID-19 vaccine has received emergency use authorisation from Chinese health authorities. The approval from the National Medical Products Administration means CSPC is the first company cleared to provide an mRNA vaccine in China - but it comes as COVID cases decline across the country after a recent surge.